Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | CLL: Susan O’Brien’s top ASCO 2019 picks

Susan O’Brien • 1 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Acalabrutinib Ibrutinib Lisocabtagene maraleucel

Susan O’Brien, MD, of the University of California Irvine, Irvine, CA, discusses her top chronic lymphocytic leukemia picks at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Susan O’Brien

Venetoclax and obinutuzumab combination therapy for CLL
2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
CAR T-cell therapy updates in CLL
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
CLL RESONATE-2: Five-year follow-up
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Susan O’Brien • 6 Dec 2025
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Susan O’Brien • 8 Dec 2025
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Susan O’Brien • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Susan O’Brien • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals